The approval intensifies competition with Regeneron in the small market for fibrodysplasia ossificans progressiva, a disorder that causes abnormal bone growth.

A weekly injection gives patients an alternative to daily long-acting insulin, a large convenience shift in a crowded diabetes market.

The two-pill regimen expands options in advanced renal cell carcinoma even as regulators and analysts question the absence of an overall survival gain.

The withdrawal sets back one of the partners' closely watched antibody-drug conjugate programs.

The European clearance opens a new treatment class for an MS subtype that has had few options.

Investor enthusiasm around Moderna's cancer vaccine and reported UAE investment talks drove shares to a four-year peak.

The partnership adds to a wave of large pharma bets on AI-driven drug discovery for oncology.

The long-term data bolsters the case for earlier use of the CAR-T therapy in relapsed or refractory multiple myeloma.

The targeted therapy adds an option for a rare and hard-to-treat cancer with limited treatments.

The vote shapes the availability of compounded peptides, a contentious area of pharmacy regulation.

The clearance advances a next-generation gene editing program into clinical testing.

It is the first U.S. RNAi biotech IPO in more than a decade, a notable test of public market appetite for RNA medicines.

The story illustrates how federal research budget reductions are slowing trials for patients with few alternatives.

The transaction highlights surging Western interest in Chinese biotech assets amid policy and geopolitical scrutiny.

Advisory support for a multi-cancer blood test moves the screening approach closer to wider clinical use.

The personalized vaccine results are being watched as a test of the mRNA platform beyond infectious disease.

The round adds to a streak of large fundraises for AI drug discovery startups.

The results support a direct move toward mid-stage testing in pulmonary hypertension with interstitial lung disease.